Aberdeen Group plc Has $204.73 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aberdeen Group plc increased its stake in Thermo Fisher Scientific by 59.8%, owning approximately 415,557 shares worth around $204.73 million as of the recent reporting period.
• Thermo Fisher Scientific's latest earnings report shows a 2.9% year-over-year revenue growth totaling $10.86 billion, exceeding analyst expectations for both revenue and earnings per share.
• The company announced a quarterly dividend of $0.43 per share, resulting in an annualized dividend of $1.72 and a yield of 0.4%.

Aberdeen Group plc grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 59.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 415,557 shares of the medical research company's stock after purchasing an additional 155,576 shares during the period. Aberdeen Group plc owned approximately 0.11% of Thermo Fisher Scientific worth $204,730,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares in the last quarter. Capital World Investors boosted its holdings in shares of Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the last quarter. Northern Trust Corp lifted its position in Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after buying an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after acquiring an additional 115,463 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $4.92 during trading hours on Friday, reaching $489.96. 2,462,453 shares of the stock were exchanged, compared to its average volume of 3,059,810. The firm has a 50 day simple moving average of $434.83 and a 200-day simple moving average of $459.02. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The stock has a market capitalization of $185.01 billion, a P/E ratio of 28.34, a P/E/G ratio of 2.61 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $52,037,916.68. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 over the last quarter. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Barclays upped their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.